KalVista Pharmaceuticals Inc(KALV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4 | Insider Own | 17.04% | Shs Outstand | 51.2M | Perf Week | - |
| Market Cap | 1.44B | Forward P/E | 34.18 | EPS next Y | 197.53% | Insider Trans | -3.56% | Shs Float | 44.2M | Perf Month | 0.9% |
| Enterprise Value | 1.44B | PEG | - | EPS next Q | - | Inst Own | 115.54% | Short Float | 15.49% | Perf Quarter | 74.31% |
| Income | -0.20B | P/S | 1005.23 | EPS this Y | 60.1% | Inst Trans | 2.59% | Short Ratio | 1.99 | Perf Half Y | 59.76% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -97.71% | Short Interest | 6.84M | Perf YTD | 67.18% |
| Book/sh | -0.38 | P/C | 5.04 | EPS past 3/5Y | 1.05% -5.91% | ROE | -190.18% | 52W High | 0% ($27.00) | Perf Year | 90.01% |
| Cash/sh | 5.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -82.31% | 52W Low | 174.67% ($9.83) | Perf 3Y | 172.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -13.14% | Gross Margin | -9.33% | Volatility(W/M) | 0.07% 0.18% | Perf 5Y | -6.57% |
| Dividend TTM | - | EV/Sales | 1004.73 | Sales Y/Y TTM | - | Oper. Margin | -14220.9% | ATR (14) | 0.23 | Perf 10Y | 70.67% |
| Dividend Ex-Date | - | Quick Ratio | 5.1 | EPS Q/Q | 59% | Profit Margin | -14242.57% | RSI (14) | 75.88 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.17 | Sales Q/Q | - | SMA20 | 0.53% ($26.86) | Beta | -0.1 | Target Price | $27 |
| Payout | - | Debt/Eq | - | Earnings | 2026/3/25 | SMA50 | 12.45% ($24.01) | Rel Volume | 0 | Prev Close | $27 |
| Employees | 275 | LT Debt/Eq | - | EPS/Sales Surpr. | 11.5% -100% | SMA200 | 60.3% ($16.84) | Avg Volume(3M) | 3.45M | Price | $27 |
| IPO | 2015/4/9 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
💊 KalVista Pharmaceuticals (KALV) is a biotech company that develops oral small-molecule drugs targeting protease enzymes such as plasma kallikrein. Its lead product, sebetralstat—an oral, on-demand treatment for hereditary angioedema—received U.S. FDA approval, marking its entry into the commercialization stage, and the company is pursuing expansion into additional indications.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
KALV has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +60.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $100,523. Peers typically go for $1,268.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -6.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 115.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #132 of 598 in the industry
Based on market cap of $1B.
LYCA#129 Lycia Therapeutics Inc $1B PER - 
TYRA#130 Tyra Biosciences Inc $1B PER - 
ANAB#131 AnaptysBio Inc $1B PER 7.5 KALV#132 KalVista Pharmaceuticals Inc $1B PER - 
GHRS#132 GH Research PLC $1B PER - 
FAQ
What kind of company is KALV?
KALV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KALV?
The market cap of KALV is approximately $1.4B, ranking 2,369 within its sector.
What is the 52-week high and low for KALV?
KALV has recorded a 52-week high of $27.00 and a low of $9.83.
